Retatrutide is the most talked-about molecule in obesity medicine and it is not approved anywhere. It is an Eli Lilly compound that acts on three receptors rather than two, adding glucagon to the GLP-1 and GIP targets, which appears to increase energy expenditure as well as reducing appetite. Mid-stage results showed about twenty four percent weight loss at forty eight weeks, and the first large late-stage trial, enrolling two thousand three hundred and thirty nine participants, reported up to thirty percent at two years. Those are the strongest weight loss figures anyone has published. It is still investigational, which means the only legitimate way to receive it is inside a Lilly trial, and the material sold online has no approved reference product to be compared against.